Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Barnett

Showing results (401-410 of 409) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 409 results.
Journal of Virology|November 16, 2018
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein BoostBenedikt Asbach, Karen V Kibler, Josef Köstler, et al.
Journal of Virology|February 12, 2016
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensBenedikt Asbach, Alexander Kliche, Josef Köstler, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Plos One|November 16, 2012
HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesPaolo Monini, Aurelio Cafaro, Indresh K Srivastava, et al.
Nature Medicine|May 31, 2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionMonica Vaccari, Shari N Gordon, Slim Fourati, et al.
The New England Journal of Medicine|March 24, 2021
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in AdultsGlenda E Gray, Linda-Gail Bekker, Fatima Laher, et al.
Pageof 41

Showing results (401-410 of 409) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 409 results.
Journal of Virology|November 16, 2018
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein BoostBenedikt Asbach, Karen V Kibler, Josef Köstler, et al.
Journal of Virology|February 12, 2016
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensBenedikt Asbach, Alexander Kliche, Josef Köstler, et al.
Plos Medicine|March 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trialZoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Plos One|November 16, 2012
HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodiesPaolo Monini, Aurelio Cafaro, Indresh K Srivastava, et al.
Nature Medicine|May 31, 2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisitionMonica Vaccari, Shari N Gordon, Slim Fourati, et al.
The New England Journal of Medicine|March 24, 2021
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in AdultsGlenda E Gray, Linda-Gail Bekker, Fatima Laher, et al.
Pageof 41